Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

Arterial Stiffness Gradient, Systemic Reflection Coefficient, and Pulsatile Pressure Wave Transmission in Essential Hypertension.

London GM, Pannier B, Safar ME.

Hypertension. 2019 Dec;74(6):1366-1372. doi: 10.1161/HYPERTENSIONAHA.119.13387. Epub 2019 Nov 4.

PMID:
31679422
2.

Erratum to: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Aug 9. pii: gfz137. doi: 10.1093/ndt/gfz137. [Epub ahead of print] No abstract available.

PMID:
31397476
3.

Arterial Stiffness in the Heart Disease of CKD.

Zanoli L, Lentini P, Briet M, Castellino P, House AA, London GM, Malatino L, McCullough PA, Mikhailidis DP, Boutouyrie P.

J Am Soc Nephrol. 2019 Jun;30(6):918-928. doi: 10.1681/ASN.2019020117. Epub 2019 Apr 30.

PMID:
31040188
4.

Erratum.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 28. pii: gfz047. doi: 10.1093/ndt/gfz047. [Epub ahead of print] No abstract available.

PMID:
30820538
5.

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407.

PMID:
30753708
6.

Erratum.

Untersteller K, Seiler-Mußler S, Mallamaci F, Fliser D, London GM, Zoccali C, Heine GH.

Nephrol Dial Transplant. 2019 Jan 21. doi: 10.1093/ndt/gfy408. [Epub ahead of print] No abstract available.

PMID:
30668741
7.

Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients.

Fouque D, Roth H, Darné B, Bouchet JL, Daugas E, Drüeke TB, Hannedouche T, Jean G, London GM.

Clin Kidney J. 2018 Oct;11(5):710-719. doi: 10.1093/ckj/sfy015. Epub 2018 Mar 15.

8.

Is progression of coronary artery calcification influenced by modality of renal replacement therapy? A systematic review.

Jansz TT, Verhaar MC, London GM, van Jaarsveld BC.

Clin Kidney J. 2018 Jun;11(3):353-361. doi: 10.1093/ckj/sfx124. Epub 2017 Oct 26.

9.

Common Carotid Artery Diameter and Risk of Cardiovascular Events and Mortality: Pooled Analyses of Four Cohort Studies.

Sedaghat S, van Sloten TT, Laurent S, London GM, Pannier B, Kavousi M, Mattace-Raso F, Franco OH, Boutouyrie P, Ikram MA, Stehouwer CDA.

Hypertension. 2018 Jul;72(1):85-92. doi: 10.1161/HYPERTENSIONAHA.118.11253. Epub 2018 May 21.

PMID:
29785959
10.

Arterial Stiffness in Chronic Kidney Disease and End-Stage Renal Disease.

London GM.

Blood Purif. 2018;45(1-3):154-158. doi: 10.1159/000485146. Epub 2018 Jan 26. Review.

11.

Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study.

Fouque D, Roth H, Darné B, Jean-Bouchet L, Daugas E, Drüeke TB, Hannedouche T, Jean G, London GM; French Phosphorus and Calcium Observatory.

Clin Kidney J. 2018 Feb;11(1):73-79. doi: 10.1093/ckj/sfx101. Epub 2017 Sep 23.

12.

Validation of echocardiographic criteria for the clinical diagnosis of heart failure in chronic kidney disease.

Untersteller K, Seiler-Mußler S, Mallamaci F, Fliser D, London GM, Zoccali C, Heine GH.

Nephrol Dial Transplant. 2018 Apr 1;33(4):653-660. doi: 10.1093/ndt/gfx197.

PMID:
29106648
13.

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F.

Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209.

PMID:
28431138
14.

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C.

Nephrol Dial Transplant. 2017 Apr 1;32(4):620-640. doi: 10.1093/ndt/gfw433. Review.

PMID:
28340239
15.

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, Halimi JM, Heine G, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verharr MC, Wiecek A, Wuerzner G, London GM, Zoccali C.

J Hypertens. 2017 Apr;35(4):657-676. doi: 10.1097/HJH.0000000000001283.

PMID:
28157814
16.

High Pulse-Wave Velocity Defines a Very High Cardiovascular Risk Cohort of Dialysis Patients under Age 60.

Ferreira JP, Girerd N, Pannier B, Rossignol P, London GM.

Am J Nephrol. 2017;45(1):72-81. doi: 10.1159/000453338. Epub 2016 Nov 30.

PMID:
27898419
17.

Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project.

Gargani L, Sicari R, Raciti M, Serasini L, Passera M, Torino C, Letachowicz K, Ekart R, Fliser D, Covic A, Balafa O, Stavroulopoulos A, Massy ZA, Fiaccadori E, Caiazza A, Bachelet T, Slotki I, Shavit L, Martinez-Castelao A, Coudert-Krier MJ, Rossignol P, Kraemer TD, Hannedouche T, Panichi V, Wiecek A, Pontoriero G, Sarafidis P, Klinger M, Hojs R, Seiler-Mußler S, Lizzi F, Onofriescu M, Zarzoulas F, Tripepi R, Mallamaci F, Tripepi G, Picano E, London GM, Zoccali C.

Nephrol Dial Transplant. 2016 Dec;31(12):1982-1988. Epub 2016 Sep 26.

PMID:
27672089
18.

The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study.

Torino C, Gargani L, Sicari R, Letachowicz K, Ekart R, Fliser D, Covic A, Siamopoulos K, Stavroulopoulos A, Massy ZA, Fiaccadori E, Caiazza A, Bachelet T, Slotki I, Martinez-Castelao A, Coudert-Krier MJ, Rossignol P, Gueler F, Hannedouche T, Panichi V, Wiecek A, Pontoriero G, Sarafidis P, Klinger M, Hojs R, Seiler-Mussler S, Lizzi F, Siriopol D, Balafa O, Shavit L, Tripepi R, Mallamaci F, Tripepi G, Picano E, London GM, Zoccali C.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2005-2011. Epub 2016 Sep 22.

19.

Estimating central blood pressure in the extreme vascular phenotype of advanced kidney disease.

Boutouyrie P, London GM, Sharman JE.

Kidney Int. 2016 Oct;90(4):736-9. doi: 10.1016/j.kint.2016.06.039.

PMID:
27633868
20.

Multiphasic effects of blood pressure on survival in hemodialysis patients.

Hannedouche T, Roth H, Krummel T, London GM, Jean G, Bouchet JL, Drüeke TB, Fouque D; French Observatory.

Kidney Int. 2016 Sep;90(3):674-84. doi: 10.1016/j.kint.2016.05.025.

21.

Progress and Perspectives on HIV-1 microbicide development.

Alexandre KB, Mufhandu HT, London GM, Chakauya E, Khati M.

Virology. 2016 Oct;497:69-80. doi: 10.1016/j.virol.2016.07.004. Epub 2016 Jul 16. Review.

22.

Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population-Based Cohort (STANISLAS Cohort Study).

Ferreira JP, Girerd N, Bozec E, Machu JL, Boivin JM, London GM, Zannad F, Rossignol P.

J Am Heart Assoc. 2016 Jun 16;5(6). pii: e003529. doi: 10.1161/JAHA.116.003529.

23.

Clinical management of the uraemic syndrome in chronic kidney disease.

Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, Massy ZA, Ortiz A, Rossignol P, Wiecek A, Zoccali C, London GM; European Renal Association European Dialysis; Transplant Association (ERA-EDTA) European Renal; Cardiovascular Medicine (EURECA-m) working group.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):360-73. doi: 10.1016/S2213-8587(16)00033-4. Epub 2016 Mar 3. Review. Erratum in: Lancet Diabetes Endocrinol. 2016 Apr;4(4):e4.

PMID:
26948372
24.

Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.

Merle E, Roth H, London GM, Jean G, Hannedouche T, Bouchet JL, Drüeke T, Fouque D, Daugas E; French Calcium and Phosphate Observatory.

Kidney Int. 2016 Mar;89(3):666-74. doi: 10.1016/j.kint.2015.12.001. Epub 2016 Feb 2.

25.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Epub 2015 Nov 27. Review.

26.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

27.

Carotid stiffness is associated with incident stroke: a systematic review and individual participant data meta-analysis.

van Sloten TT, Sedaghat S, Laurent S, London GM, Pannier B, Ikram MA, Kavousi M, Mattace-Raso F, Franco OH, Boutouyrie P, Stehouwer CDA.

J Am Coll Cardiol. 2015 Nov 10;66(19):2116-2125. doi: 10.1016/j.jacc.2015.08.888. Review.

28.

The double challenge of resistant hypertension and chronic kidney disease.

Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D; ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network.

Lancet. 2015 Oct 17;386(10003):1588-98. doi: 10.1016/S0140-6736(15)00418-3. Review.

PMID:
26530623
29.

Aortic Aging in ESRD: Structural, Hemodynamic, and Mortality Implications.

London GM, Safar ME, Pannier B.

J Am Soc Nephrol. 2016 Jun;27(6):1837-46. doi: 10.1681/ASN.2015060617. Epub 2015 Oct 16.

30.

Hypertension and chronic kidney disease: respective contribution of mean and pulse pressure and arterial stiffness.

Kheder-Elfekih R, Yannoutsos A, Blacher J, London GM, Safar ME.

J Hypertens. 2015 Oct;33(10):2010-5. doi: 10.1097/HJH.0000000000000711.

PMID:
26237563
31.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
32.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4.

PMID:
26040438
33.

Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Pelletier S, Confavreux CB, Haesebaert J, Guebre-Egziabher F, Bacchetta J, Carlier MC, Chardon L, Laville M, Chapurlat R, London GM, Lafage-Proust MH, Fouque D.

Osteoporos Int. 2015 Aug;26(8):2165-74. doi: 10.1007/s00198-015-3127-9. Epub 2015 Apr 25.

PMID:
25910747
34.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

35.

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.

36.

Isolation and characterization of 2'-F-RNA aptamers against whole HIV-1 subtype C envelope pseudovirus.

London GM, Mayosi BM, Khati M.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):428-33. doi: 10.1016/j.bbrc.2014.11.101. Epub 2014 Dec 4.

PMID:
25482445
37.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators.

J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000570.

38.

Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).

Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di Paolo S, Kribben A, Fliser D, Messner H, McNeil J, Stevens P, Santoro A, De Francisco AL, Percheson P, Potamianou A, Foucher A, Fife D, Mérit V, Vercammen E; PRIMS study group.

Nephrol Dial Transplant. 2015 Mar;30(3):451-60. doi: 10.1093/ndt/gfu297. Epub 2014 Sep 19.

39.

Ankle-brachial index and bone turnover in patients on dialysis.

London GM, Marchais SJ, Guérin AP, de Vernejoul MC.

J Am Soc Nephrol. 2015 Feb;26(2):476-83. doi: 10.1681/ASN.2014020169. Epub 2014 Sep 17.

40.

Mechanisms of arterial calcifications and consequences for cardiovascular function.

London GM.

Kidney Int Suppl (2011). 2013 Dec;3(5):442-445. Review.

41.

Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure.

Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM; Board of the EURECA-m Working Group of ERA-EDTA.

Lancet. 2014 May 24;383(9931):1831-43. doi: 10.1016/S0140-6736(14)60384-6. Review.

PMID:
24856028
42.

The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.

Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG.

J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9.

PMID:
24108314
43.

Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry.

Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C, London GM.

Nephrol Dial Transplant. 2014 Feb;29(2):232-9. doi: 10.1093/ndt/gft309. Epub 2013 Sep 30. Review.

PMID:
24084326
44.

Vascular calcifications, arterial aging and arterial remodeling in ESRD.

London GM, Pannier B, Marchais SJ.

Blood Purif. 2013;35(1-3):16-21. doi: 10.1159/000345172. Epub 2013 Jan 22.

45.

Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?

Fouque D, Roth H, Pelletier S, London GM, Hannedouche T, Jean G, Bouchet JL, Drüeke T.

Nephrol Dial Transplant. 2013 Feb;28(2):360-7. doi: 10.1093/ndt/gfs404. Epub 2012 Nov 6.

PMID:
23136211
46.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

47.

Bone-vascular cross-talk.

London GM.

J Nephrol. 2012 Sep-Oct;25(5):619-25. doi: 10.5301/jn.5000187. Review.

PMID:
22711433
48.

Arterial stiffness and pulse pressure in CKD and ESRD.

Briet M, Boutouyrie P, Laurent S, London GM.

Kidney Int. 2012 Aug;82(4):388-400. Review.

49.

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.

Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS.

Nephrol Dial Transplant. 2012 Jul;27(7):2872-9. doi: 10.1093/ndt/gfr777. Epub 2012 Apr 23.

PMID:
22529163
50.

Monocyte subpopulations and cardiovascular risk in chronic kidney disease.

Heine GH, Ortiz A, Massy ZA, Lindholm B, Wiecek A, Martínez-Castelao A, Covic A, Goldsmith D, Süleymanlar G, London GM, Parati G, Sicari R, Zoccali C, Fliser D; European Renal and Cardiovascular Medicine (EURECA‑m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).

Nat Rev Nephrol. 2012 Mar 13;8(6):362-9. doi: 10.1038/nrneph.2012.41. Review.

PMID:
22410492

Supplemental Content

Loading ...
Support Center